NasdaqGM - Nasdaq Real Time Price USD

ImmunoPrecise Antibodies Ltd. (IPA)

1.2100 -0.0100 (-0.82%)
As of 10:19 AM EDT. Market Open.
Currency in CAD All numbers in thousands
Download
Breakdown
TTM
4/30/2023
4/30/2022
4/30/2021
4/30/2020
Total Revenue
22,629.0000
20,665.0000
19,364.0000
17,912.0000
14,058.0000
Cost of Revenue
10,577.0000
9,102.0000
8,381.0000
6,374.0000
6,024.0000
Gross Profit
12,052.0000
11,563.0000
10,983.0000
11,538.0000
8,034.0000
Operating Expense
29,564.0000
39,782.0000
27,656.0000
15,714.0000
11,860.0000
Operating Income
-17,512.0000
-28,219.0000
-16,673.0000
-4,176.0000
-3,826.0000
Net Non Operating Interest Income Expense
555.0000
240.0000
194.0000
-581.0000
-1,385.0000
Other Income Expense
43.0000
227.0000
631.0000
-1,238.0000
-82.0000
Pretax Income
-16,914.0000
-27,752.0000
-15,848.0000
-5,995.0000
-5,293.0000
Tax Provision
-893.0000
-1,192.0000
861.0000
1,345.0000
-346.0000
Net Income Common Stockholders
-16,021.0000
-26,560.0000
-16,709.0000
-7,340.0000
-4,947.0000
Diluted NI Available to Com Stockholders
-16,021.0000
-26,560.0000
-16,709.0000
-7,340.0000
-4,947.0000
Basic EPS
-0.65
-1.07
-0.85
-0.45
-0.36
Diluted EPS
-0.65
-1.07
-0.85
-0.45
-0.36
Basic Average Shares
25,018.9200
24,897.1850
19,688.4870
16,474.3500
13,628.8960
Diluted Average Shares
25,018.9200
24,897.1850
19,688.4870
16,474.3500
13,628.8960
Rent Expense Supplemental
--
--
168.0000
191.0000
128.0000
Total Expenses
40,141.0000
48,884.0000
36,037.0000
22,088.0000
17,884.0000
Net Income from Continuing & Discontinued Operation
-16,021.0000
-26,560.0000
-16,709.0000
-7,340.0000
-4,947.0000
Normalized Income
-16,061.7298
-26,777.2499
-17,174.6149
-6,430.0700
-4,870.3603
Interest Income
592.0000
270.0000
279.0000
282.0000
52.0000
Interest Expense
37.0000
30.0000
85.0000
863.0000
1,437.0000
Net Interest Income
555.0000
240.0000
194.0000
-581.0000
-1,385.0000
EBIT
-16,877.0000
-27,722.0000
-15,763.0000
-5,132.0000
-3,856.0000
EBITDA
-10,359.0000
-21,037.0000
-11,994.0000
-1,419.0000
-449.0000
Reconciled Cost of Revenue
7,967.0000
6,831.0000
6,625.0000
5,398.0000
5,190.0000
Reconciled Depreciation
6,518.0000
6,685.0000
3,769.0000
3,713.0000
3,407.0000
Net Income from Continuing Operation Net Minority Interest
-16,021.0000
-26,560.0000
-16,709.0000
-7,340.0000
-4,947.0000
Total Unusual Items Excluding Goodwill
43.0000
227.0000
631.0000
-1,238.0000
-82.0000
Total Unusual Items
43.0000
227.0000
631.0000
-1,238.0000
-82.0000
Normalized EBITDA
-10,402.0000
-21,264.0000
-12,625.0000
-181.0000
-367.0000
Tax Rate for Calcs
0.0001
0.0000
0.0003
0.0003
0.0001
Tax Effect of Unusual Items
2.2702
9.7501
165.3851
-328.0700
-5.3603
4/30/2020 - 1/7/2002

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CERO CERo Therapeutics Holdings, Inc.
1.4200
-0.70%
 
BRTX BioRestorative Therapies, Inc.
1.2300
-3.16%
 
SNSE Sensei Biotherapeutics, Inc.
0.9900
-0.17%
 
SILO Silo Pharma, Inc.
1.8207
-3.15%
 
RLYB Rallybio Corporation
1.5500
-1.90%
 
FWBI First Wave BioPharma, Inc.
2.8151
-6.78%
 
LVTX LAVA Therapeutics N.V.
2.6367
-3.77%
 
OCEAW Ocean Biomedical, Inc.
0.1174
+6.73%
 
GRI GRI Bio, Inc.
0.4380
+0.14%
 
CZO.V Ceapro Inc.
0.2400
0.00%